We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Caribou Biosciences Inc | NASDAQ:CRBU | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.14 | -7.95% | 1.62 | 1.65 | 1.74 | 1.79 | 1.615 | 1.77 | 1,797,600 | 21:01:33 |
From Jun 2023 to Jun 2024
By Colin Kellaher
Shares of Caribou Biosciences surged in premarket trading Thursday after the clinical-stage, genome-editing biopharmaceutical company said it received a $25 million equity investment at a healthy premium from drug giant Pfizer.
Caribou shares were recently up 36% to $5.56 in premarket trading.
The Berkeley, Calif.-based company said Pfizer bought about 4.69 million shares at $5.33 apiece, nearly 31% above Wednesday's closing price of $4.08.
With the investment, Pfizer is Caribou's second-largest shareholder, according to FactSet data.
Caribou said it would use the new funds to advance CB-011, an immune cloaked allogeneic CAR-T cell therapy currently in a Phase 1 study in patients with relapsed or refractory multiple myeloma.
The company said it would maintain full ownership and control of its pipeline of allogeneic CAR-T and CAR-NK cell therapies.
Caribou also said Sriram Krishnaswami, Pfizer's head of multiple myeloma development, joined its scientific advisory board.
Write to Colin Kellaher at colin.kellaher@wsj.com
(END) Dow Jones Newswires
July 06, 2023 09:19 ET (13:19 GMT)
Copyright (c) 2023 Dow Jones & Company, Inc.
1 Year Caribou Biosciences Chart |
1 Month Caribou Biosciences Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
